Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information.
作者信息
Talamonti Marina, Galluzzo Marco
机构信息
Dermatology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy.
Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
出版信息
Ann Transl Med. 2020 Aug;8(15):971. doi: 10.21037/atm.2020.04.05.
Abstract
摘要
相似文献
1
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information.
Ann Transl Med. 2020 Aug;8(15):971. doi: 10.21037/atm.2020.04.05.
2
A clinical approach to pharmacogenetics.
Neth J Med. 2013 Apr;71(3):145-52.
3
Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.
Pharmacogenomics. 2006 Jul;7(5):783-92. doi: 10.2217/14622416.7.5.783.
4
Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
Hum Immunol. 2012 Feb;73(2):164-7. doi: 10.1016/j.humimm.2011.12.002. Epub 2011 Dec 8.
5
Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.
Trends Pharmacol Sci. 2004 Apr;25(4):193-200. doi: 10.1016/j.tips.2004.02.007.
6
Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.
J Rheumatol. 2017 Jun;44(6):835-843. doi: 10.3899/jrheum.151476. Epub 2017 Apr 1.
7
The emerging role of pharmacogenomics in biologics.
Clin Pharmacol Ther. 2007 Oct;82(4):466-71. doi: 10.1038/sj.clpt.6100334. Epub 2007 Aug 22.
8
The Importance of New Generation Sequencing (NGS) HLA Typing in Renal Transplantation-Preliminary Report.
Transplant Proc. 2018 Jul-Aug;50(6):1605-1615. doi: 10.1016/j.transproceed.2018.05.005. Epub 2018 Jun 21.
9
Genotyping HLA-B*5801 for Allopurinol-Induced Severe Cutaneous Adverse Reactions: An Accurate and Prompt Method.
Clin Transl Sci. 2015 Dec;8(6):834-6. doi: 10.1111/cts.12365. Epub 2015 Dec 14.
10
Pharmacogenetics in clinical dermatology.
Br J Dermatol. 2002 Jan;146(1):2-6. doi: 10.1046/j.1365-2133.2002.04466.x.
本文引用的文献
1
Clinical Features and Genetic Polymorphism in Chinese Patients with Erythrodermic Psoriasis in a Single Dermatologic Clinic.
Mol Diagn Ther. 2020 Feb;24(1):85-93. doi: 10.1007/s40291-019-00441-x.
2
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience.
Expert Opin Biol Ther. 2020 Jan;20(1):95-104. doi: 10.1080/14712598.2020.1684472. Epub 2019 Oct 30.
3
The contribution of IL-17 to the development of autoimmunity in psoriasis.
Innate Immun. 2019 Aug;25(6):337-343. doi: 10.1177/1753425919852156. Epub 2019 May 24.
4
Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis.
JAMA Dermatol. 2019 Jun 1;155(6):708-715. doi: 10.1001/jamadermatol.2019.0098.
5
HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.
J Allergy Clin Immunol. 2019 Jun;143(6):2120-2130. doi: 10.1016/j.jaci.2018.11.038. Epub 2018 Dec 20.
6
Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence.
Sci Rep. 2018 Oct 30;8(1):16068. doi: 10.1038/s41598-018-34293-y.
7
Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis.
Psoriasis (Auckl). 2018 Mar 23;8:7-11. doi: 10.2147/PTT.S161437. eCollection 2017.
8
Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.
Eur J Dermatol. 2017 Oct 1;27(5):528-530. doi: 10.1684/ejd.2017.3071.
9
Drug survival of biologic treatments in psoriasis: a systematic review.
J Dermatolog Treat. 2018 Aug;29(5):460-466. doi: 10.1080/09546634.2017.1398393. Epub 2017 Nov 10.
10
Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.
J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1183-1187. doi: 10.1111/jdv.14200. Epub 2017 Mar 29.
Zotero 插件